Proprietary Gen 2 technology

Leveraging the initial success of the NCI processes, we set out to develop centralized, scalable and proprietary processes to manufacture Iovance TIL therapies. Our proprietary Gen 2 technology includes manufacturing and logistical efficiencies aimed at further optimizing treatment, decreasing production time and streamlining distribution processes. Today, more than 500 patients have been treated with investigational TIL therapy from Iovance, with a manufacturing success rate above 90%.

Streamlined 22-day GMP manufacturing process

1

PATIENT INTAKE

Patient Intake
2

TUMOR SAMPLE PROCUREMENT

TUMOR SAMPLE PROCUREMENT
3

NMA-LD

NMA-LD
4

TIL INFUSION

TIL INFUSION
5

IL-2 INFUSIONS

IL-2 INFUSIONS
6

RECOVERY/ DISCHARGE

Discharge
Gen 2 Process: 22 Days Image
 
Gen 2 Process: 22 Days
 
1
PATIENT INTAKE
Patient Intake
2
TUMOR SAMPLE PROCUREMENT
TUMOR SAMPLE PROCUREMENT
3
NMA-LD
NMA-LD
4
TIL INFUSION
TIL INFUSION
5
IL-2 INFUSIONS
IL-2 INFUSIONS
6
RECOVERY/ DISCHARGE
Discharge
Gen 2 Process: 22 Days Image

Our 16-day, Gen 3 process

In some of our clinical trials, we are also exploring a Gen 3 process which reduces manufacturing to 16 days. The third generation of our process is expected to reduce the wait time between initial tumor sample and infusion for patients.

GMP=good manufacturing practice; IL-2=interleukin-2; NMA-LD=nonmyeloablative lymphodepletion

Learn About Our Intellectual Property

TIL therapy is an investigational therapy and has not been approved for any indication by the Food and Drug Administration (FDA) or any other regulatory agency. The safety and efficacy of this therapy have not been determined.